Leeds, UK
Joined April 2016
- Tweets222
- Following130
- Followers2.2K
- Likes139
This month's @ScienceMagazine Special Issue: The Systemic Microbiome.
"Understanding the ecology and the mechanisms of cross-talk between host and microbiota will one day contribute to preventing and treating a spectrum of human diseases."
science.org/toc/science/376/…
We are pleased to be presenting our Phase II trial of #LiveBiotherapeutic MRx0518 with Bavencio as a first-line maintenance therapy for #UrothelialCarcinoma at #ASCO22
Session: Genitourinary Cancer - Kidney and Bladder. Saturday, June 4, 2022 at 13:15 CDT
$LBPS #DDDD
On #clinicaltrialsday , @ParkinsonsUK have written about one of 4D pharma's lunch and learn sessions, highlighting the importance of engaging patients in clinical research.
tinyurl.com/2p9bfsuj
#microbiome #DDDD $LBPS
Results from Part A of @4dpharmaplc's trial of #LiveBiotherapeutic MRx-4DP0004 for the treatment of #asthma have been selected as a late-breaking abstract at #ATS2022 @atscommunity
These results support the potential of MRx-4DP0004 as a novel oral immunomodulator asthma therapy
CEO Duncan Peyton stopped by the #BusinessOfBiotech podcast with @mattpillar @BioProcessOL @Cytiva to discuss how @4dpharmaplc is defining a new class of drug with our #LiveBiotherapeutics and the challenges overcome along the way
bit.ly/3KMTozs
#microbiome #DDDD $LBPS
On #WorldParkinsonsDay we are proud to be working with @ParkinsonsUK to raise awareness and support research into new therapies for #Parkinsons
Brave souls from @4dpharmaplc will be attempting the infamous @ToughMudder and you can show your support at:
justgiving.com/fundraising/4…
Today Dr Imke Mulder, EVP Research, will present at the Microbiome & Probiotics R&D and Business Collaboration Forum #MicrobiomeForum on developing #LiveBiotherapeutics for neurodegenerative disease as we look ahead to initiating a first-in-human trial in #Parkinsons in 2022
Join us in 30 minutes us for a conference call and webcast to discuss this morning's results for MRx0518 and Keytruda in renal cell carcinoma (RCC) and current treatment landscape, alongside KOLs @PGrivasMDPhD and @DrScottTagawa
Register via 4dpharmaplc.com/en/newsroom/…
$LBPS #DDDD
Today we announced the #renalcellcarcinoma group in Part B of our Phase I/II study of #LiveBiotherapeutic MRx0518 with #Keytruda has met the primary efficacy endpoint ahead of full enrollment.
Read the full release at 4dpharmaplc.com/en/newsroom/…
$LBPS #DDDD
Today we announced the #renalcellcarcinoma group in Part B of our Phase I/II study of #LiveBiotherapeutic MRx0518 with #Keytruda has met the primary efficacy endpoint ahead of full enrollment.
Read the full release at 4dpharmaplc.com/en/newsroom/…
$LBPS #DDDD
4D Gets Green Light to Test First Live Biotherapeutic for Parkinson's
"With IND approval, the therapeutics have become the first LBPs for Parkinson’s disease cleared by the FDA"
@biospace #Parkinsons #microbiome #GutBrainAxis #DDDD $LBS
biospace.com/article/4d-gets…
MRx0005 and MRx0029 #Parkinsons IND approvals covered in today's BioPharma Reporter, as well as a re-cap of our #asthma data released in January for MRx-4DP0004
biopharma-reporter.com/Artic…
#DDDD $LBPS
Today we announced that the US FDA has cleared IND applications for @4dpharmaplc’s #LiveBiotherapeutics MRx0005 and MRx0029 for the treatment of #Parkinsons, and Phase I trial in patients is expected to commence mid-2022
4dpharmaplc.com/en/newsroom/…
#GutBrainAxis #microbiome
Today marks @uicc World Cancer Day - raising awareness of one of the leading causes of death worldwide.
4D Pharma are proud to contribute to helping patients through developing novel and safe LBPs. Learn more at tinyurl.com/4DLBPS
#WorldCancerDay #Cancer #DDDD $DDDD $LBPS
#ICYMI Replays of two recent events available via the Events page of our website at 4dpharmaplc.com/en/newsroom/…
- 27 Jan, MRx-4DP0004 #Asthma Phase 1/2 Part A Results with Prof. Chris Brightling
- 31 Jan, #LiveBiotherapeutics for #Parkinsons, hosted by NoSPRIG, DRIG, @ParkinsonsUK
We caught up with @GENbio to discuss how @4dpharmaplc approaches the development of 'Bacteria as Therapeutics', from the MicroRx platform and #LiveBiotherapeutic discovery, to in-house manufacturing and clinical development
genengnews.com/topics/biopro…
#DDDD $LBPS #microbiome
Today @4dpharmaplc will discuss how we are developing #LiveBiotherapeutics targeting the #GutBrainAxis to treat #Parkinsons at an event hosted by North of Scotland Parkinson’s Research Interest Group (NoSPRIG) and Dundee Research Interest Group (DRIG)
parkinsons-org-uk.zoom.us/me…
@4dpharmaplc's involvement in the @MichaelJFoxOrg #MJFF #PPMI and how this is supporting our clinical development of LBPs for the #GutBrainAxis is spotlighted in this month's special edition
Read the full report at view.michaeljfox-email.org/?…
#Parkinsons #microbiome
Today @4dpharmaplc announced additional details of the positive results from Part A of our Phase I/II trial of #LiveBiotherapeutic MRx-4DP0004 for #asthma and will host a conference call & webcast to discuss the results
4dpharmaplc.com/en/newsroom/…
$LBPS #DDDD #microbiome
Duncan Peyton, CEO: "Beyond achieving the primary endpoint, we see positive trends in multiple secondary endpoints of efficacy that we will be assessing in Part B, including statistical significance at all time points in the primary endpoint for Part B"
#asthma #microbiome
@4dpharmaplc will host a webcast today Thurs 27 Jan at 8:00am ET / 1:00pm GMT, with KOL Prof. Chris Brightling, to discuss the MRx-4DP0004 Phase I/II Part A results and #asthma treatment landscape
Join via the Events page of our website at 4dpharmaplc.com/en/newsroom/…
#DDDD $LBPS